Literature DB >> 21485671

Antimicrobial utilisation in 37 Australian and New Zealand intensive care units.

J M Dulhunty1, D Paterson, S A R Webb, J Lipman.   

Abstract

This multi-centre point prevalence study reports on antimicrobial dosing patterns, including dose, mode of administration and type of infection, in 37 Australian and New Zealand intensive care units. Of 422 patients admitted to an intensive care unit on 8 May 2007, 195 patients (46%) received antimicrobial treatment, 123 patients (29%) received no antimicrobials and 104 patients (25%) received prophylactic antimicrobials only. Dosing data were available for 331 antimicrobials used to treat 225 infections in 193 patients. Respiratory (40%), abdominal (13%) and blood stream (12%) infections were most common. For adult patients, ticarcillin/clavulanate (23% or 40/177), meropenem (20% or 35/177) and vancomycin (18% or 32/177) were the most frequently used antibiotics; vancomycin was most commonly used in children (31% or 5/16). The majority of antimicrobials were administered as bolus doses or infusions of less than two hours (98% or 317/323); only six patients received extended or continuous infusions. The mode of administration was unknown in eight cases (4.1%). The total defined daily dose for adult patients receiving antimicrobial therapy was 2051 defined daily doses per 1000 patient days. Our results confirm that the use of continuous infusions remains rare, despite increased interest in continuous infusions for time-dependent antibiotics.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21485671     DOI: 10.1177/0310057X1103900212

Source DB:  PubMed          Journal:  Anaesth Intensive Care        ISSN: 0310-057X            Impact factor:   1.669


  7 in total

1.  Evaluating the appropriateness of carbapenem and piperacillin-tazobactam prescribing in a tertiary care hospital in Saudi Arabia.

Authors:  Nada A Alsaleh; Hussain A Al-Omar; Ahmed Y Mayet; Alexander B Mullen
Journal:  Saudi Pharm J       Date:  2020-09-25       Impact factor: 4.330

2.  Continuous beta-lactam infusion in critically ill patients: the clinical evidence.

Authors:  Mohd H Abdul-Aziz; Joel M Dulhunty; Rinaldo Bellomo; Jeffrey Lipman; Jason A Roberts
Journal:  Ann Intensive Care       Date:  2012-08-16       Impact factor: 6.925

3.  Extended spectrum beta-lactamase carriage state among elderly nursing home residents in Beirut.

Authors:  M A Jallad; R Naoufal; J Irani; E Azar
Journal:  ScientificWorldJournal       Date:  2015-03-18

4.  Clinical outcomes of extended versus intermittent administration of piperacillin/tazobactam for the treatment of hospital-acquired pneumonia: a randomized controlled trial.

Authors:  H Bao; Y Lv; D Wang; J Xue; Z Yan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-10-28       Impact factor: 3.267

Review 5.  Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper.

Authors:  Mohd H Abdul-Aziz; Jan-Willem C Alffenaar; Matteo Bassetti; Hendrik Bracht; George Dimopoulos; Deborah Marriott; Michael N Neely; Jose-Artur Paiva; Federico Pea; Fredrik Sjovall; Jean F Timsit; Andrew A Udy; Sebastian G Wicha; Markus Zeitlinger; Jan J De Waele; Jason A Roberts
Journal:  Intensive Care Med       Date:  2020-05-07       Impact factor: 17.440

6.  Assessing the Effectiveness of Antibiotic Therapy Against Common Gram-Negative Bacteria in a Saudi Arabian Hospital Using the Drug Resistance Index.

Authors:  Muhammad Yaseen; Abdulhakeem Althaqafi; Fayssal Farahat; Asim Alsaedi; Abdulfattah Mowallad; Eili Klein; Katie Tseng; Sabiha Essack
Journal:  Cureus       Date:  2022-02-13

7.  Antimicrobial consumption in five adult intensive care units: a 33-month surveillance study.

Authors:  Hanan H Balkhy; Aiman El-Saed; Ashraf El-Metwally; Yaseen M Arabi; Sameera M Aljohany; Muayed Al Zaibag; Salim Baharoon; Adel F Alothman
Journal:  Antimicrob Resist Infect Control       Date:  2018-12-21       Impact factor: 4.887

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.